Joincare Pharmaceutical Group disclosed its 2026 half-year report. In the first half, it achieved operating revenue of 6.583 billion yuan, down 16.66% year on year. Net profit attributable to shareholders of the listed company was 648 million yuan, down 17.49% year on year. Basic earnings per share were 0.35 yuan. The company said that amid multiple pressures including deepening medical insurance cost control, the regular advancement of national centralized procurement, and the bottom of the active pharmaceutical ingredient industry cycle, operating performance faced phased pressure, but the business structure continued to improve and core competitiveness remained solid.
Joincare Pharmaceutical Group Industry Co LtdFirst-half net profit down 17.49% and revenue down 16.66% due to medical insurance cost control, centralized procurement, and API industry cycle bottom.
